HARM REDUCTION

Clear, Confident Detection.

Built For The Field. Designed Together, With Our Community.

For Forensic & Research Use Only


These tools support drug checking and harm-reduction education. They are not intended for medical diagnosis or clinical decision-making.

Today's Drug Supply Creates Layered Risks

Match the risks you’re seeing with the right tools.

Opioid Overdose Risk

  • Illicit fentanyl and fentanyl analogues remains the leading cause of overdose deaths in harm-reduction.
  • Nitazenes are a different class of ultra-potent synthetic opioids, so a fentanyl-negative result does not guarantee "no opioid risk."
  • Many programs screen for both to avoid blind spots.
Order Fentanyl Strips

Downers In The Supply

  • Screening helps programs recognize when downers may be involved, supporting better monitoring, wound care planning, and safer-use messaging.
  • People may stay heavily sedated after naloxone, sometimes becoming unresponsive again later.
  • Outreach teams are seeing more sever wounds and longer recovery times.
Order Xylazine Strips

Depressant Co-Use

  • Naloxone reverses the opioid, but sedation can linger, changing how overdoses unfold.
  • Benzodiazepines are often present alongside opioids, sometimes unknowingly.
  • Screening can help teams prepare for extended recovery windows and provide safer-use education when layered depressants are present.
Order Benzo Strips
FN
XYL
BZO

Field-Based Harm Reduction

Today's harm reduction programs operate under constant pressure, unpredictable supply, limited resources, and rising demands for community-based response.

The most effective harm reduction tools support program missions. Topaz collaborates with teams to build accessible screening tools that support outreach, strengthen care, and adapts as the supply evolves.

Overdose patterns are shifting with the market:

  • Supply volatility is reshaping overdose response
  • Naloxone recovery looks different when downers and benzos are involved
  • Programs are operating with limited time, staffing, and resources
  • Screening helps teams adapt outreach, monitoring, and education in real time

Clear Interpretation

Designed to reduce guesswork in outreach settings so teams can act with clarity, even when conditions aren’t ideal.

  • Clear instructions with simple, visual steps for end-users
  • Adaptive analytes for coverage that evolves as the supply changes
  • Accessible screening that is usable in front-line settings without complex infrastructure

Click For Instructions

Xylazine vs Medetomidine

Emerging sedatives like medetomidine are beginning to appear alongside xylazine in opioid samples, with agencies such as NIDA and SAMHSA tracking evolving overdose patterns.

Pattern/Impact XYLAZINE MEDETOMIDINE
Found alongside opioids like fentanyl Yes Emerging in some regions ⚠️
Associated with prolonged sedation Yes Yes
Linked to hard to heal/severe wounds Yes Still being evaluated ⚠️
Reversed by naloxone No No
Detected by xylazine strips Yes No
Requires its own screening --- Yes

Join The Topaz Inner Circle

Unlock Exclusive Pricing for Your Harm Reduction Program

The Topaz Inner Circle is a preferred purchasing and partnership program built for organizations on the front lines of harm reduction. Members receive priority access to test strips, preferred pricing, and the support needed to keep life-saving tools consistently available in their communities.

Our tests strips are designed to make testing fast, reliable, and accessible in community settings and outreach initiatives. 

Member Benefits

  • Preferred pricing on all Topaz harm reduction strips.
  • Dedicated support from the Topaz harm reduction team.
  • Partnership opportunities for community distribution initiatives.
  • Early access to new analytes and product releases.
HARM REDUCTION

Join the Inner Circle

Tell us what your program is working on. We'll follow up with the right tools, instructions, and support for community-based care.

Please use a work email address (no Gmail/Hotmail/Yahoo).

Tell Us About Your Program

Let us know how your program operates and what you’re seeing. We’ll follow up with the right tools and support.

Get Your Free Samples
  • SAMHSA

    “Fentanyl and Xylazine Test Strips”

    Summarized evidence on how rapid test strips (for fentanyl/xylazine) are low‑cost tools supporting overdose prevention, and details about federal funding support.

    READ MORE 
  • The Guardian

    Nitazene a new class of potentially deadly synthetic opioids is suddenly appearing around the globe, including in the US, and scientists are rushing to figure out how to detect it in the drug supply.

    READ MORE 
  • CDC

    “What You Should Know About Xylazine”

    Authoritative overview on xylazine’s emergence, health risks, prevalence in illicit supply, and why naloxone doesn’t counteract it.

    READ MORE 
  • Harm Reduction Journal

    “Perspectives on rapid fentanyl test strips as a harm reduction strategy”

    Reviews how take-home fentanyl test strips prompt safer behaviors among people who use drugs (PWUD), such as testing at home and reducing use after a positive result

    READ MORE 
  • Nature Magazine

    "Dangerous ‘nitazene’ opioids are on the rise: researchers are worried"

    Researchers who study trends in illicit drug use are concerned that this class of synthetic opioids is more potent than heroin and morphine.

    READ MORE 
  • NIDA

    "What is Xylazine"

    Xylazine, also known as “tranq,” is a veterinary tranquilizer that has been found in some illicit drug supplies. People often use xylazine without knowing it when it is added to other drugs, most frequently fentanyl.


    READ MORE 
  • The Department of Health and Human Services HHS

    HHS has reinforced overdose prevention strategies, promoting equitable access to harm reduction tools and integrating them into broader public health efforts


    READ MORE 
  • John Hopkins Bloomberg School of Public Health

    "Emerging Adulterants in the Street Drug Supply"

    As the drug supply continues to evolve, fentanyl and xylazine will likely not be the last adulterants to enter the illicit drug market.

    READ MORE 
  • AMA Journal of Ethics

    "How Should Harm Reduction Be Included in Care Continua for Patients With Opioid Use Disorder?"

    Harm reduction, represents a set of practices that aim to reduce the negative consequences of substance use by adopting patient-centered approaches.

    READ MORE